Skip to main content

Table 6 Number of patients and events according to trial group

From: Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92

  Number of patients (percentage)  
CCLG
N = 210
GPOH
N = 437
Total
First events (total) 119 (57) 204 (47) 323
 Death-treatment related 1 (0.5) 3 (1) 4
  Disease progression 3 (1) 12 (3) 15
  Unknown cause 3 (1) 1 (0.2) 3
 Distant metastases 66 (31) 148 (34) 214
[Distant metastases in those with metastatic disease at baseline] [25 (12%)] [57 (13%)] [82]
 Local relapse 29 (14) 13 (3) 42
 Local and distant relapse 16 (8) 18 (4) 34
 Relapse (unspecified site) 0 4 (1) 4
 Second malignancy 2 (1) 5 (1) 7
All deaths 105 (50) 168 (38) 273
  1. As a percentage of the number of patients from either CCLG or GPOH